(Q35037876)

5 August 2017

1 reference

title

Recent developments in inflammatory bowel disease (English)

1 reference

inflammatory bowel diseases

5 August 2017

main subject

0 references

2

Gary R Lichtenstein

1 reference

5 August 2017

Chinyu Su

1

1 reference

5 August 2017

publication date

1 November 2002

1 reference

Medical Clinics of North America

5 August 2017

published in

1 reference

5 August 2017

volume

86

1 reference

5 August 2017

issue

6

1 reference

5 August 2017

page(s)

1497-1523

1 reference

Mapping of a susceptibility locus for Crohn's disease on chromosome 16

5 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900085-8

Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900085-8

A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900085-8

Nod2, a Nod1/Apaf-1 family member that is restricted to monocytes and activates NF-kappaB

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900085-8

Human Nod1 confers responsiveness to bacterial lipopolysaccharides

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900085-8

Nod1, an Apaf-1-like activator of caspase-9 and nuclear factor-kappaB

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900085-8

Anti-Saccharomyces cerevisiae mannan antibodies combined with antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease: prevalence and diagnostic role

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900085-8

Diagnostic accuracy of serological assays in pediatric inflammatory bowel disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900085-8

Clinical utility of serodiagnostic testing in suspected pediatric inflammatory bowel disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900085-8

Marker antibody expression stratifies Crohn's disease into immunologically homogeneous subgroups with distinct clinical characteristics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900085-8

Perinuclear antineutrophil cytoplasmic antibodies in patients with Crohn's disease define a clinical subgroup

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900085-8

Perinuclear anti-neutrophil cytoplasmic antibody and refractory pouchitis. A case-control study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900085-8

High level perinuclear antineutrophil cytoplasmic antibody (pANCA) in ulcerative colitis patients before colectomy predicts the development of chronic pouchitis after ileal pouch-anal anastomosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900085-8

Perinuclear antineutrophil cytoplasmic antibody in pouchitis after proctocolectomy with ileal pouch-anal anastomosis for ulcerative colitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900085-8

Perinuclear Anti-Neutrophil Cytoplasmic Antibodies in Ulcerative Colitis after Restorative Proctocolectomy Do Not Correlate with the Presence of Pouchitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900085-8

ANCA pattern and LTA haplotype relationship to clinical responses to anti-TNF antibody treatment in Crohn's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900085-8

Sulphasalazine and salicylazosulphadimidine in ulcerative colitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900085-8

CONTROLLED TRIAL OF SULPHASALAZINE IN THE TREATMENT OF ULCERATIVE COLITIS.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900085-8

An assessment of prednisone, salazopyrin, and topical hydrocortisone hemisuccinate used as out-patient treatment for ulcerative colitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900085-8

Comparison of corticosteroid and sulphasalazine therapy in ulcerative colitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900085-8

Olsalazine sodium in the treatment of ulcerative colitis among patients intolerant of sulfasalazine. A prospective, randomized, placebo-controlled, double-blind, dose-ranging clinical trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900085-8

Oral mesalamine (Asacol) for mildly to moderately active ulcerative colitis. A multicenter study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900085-8

Sulfasalazine revisited: a meta-analysis of 5-aminosalicylic acid in the treatment of ulcerative colitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900085-8

Prophylactic effects of olsalazine v sulphasalazine during 12 months maintenance treatment of ulcerative colitis. The Danish Olsalazine Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900085-8

Optimum dose of sulphasalazine for maintenance treatment in ulcerative colitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900085-8

Treatment of ulcerative colitis with high-dose 5-aminosalicylic acid enemas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900085-8

Maintenance treatment of ulcerative proctitis with mesalazine suppositories: a double-blind placebo-controlled trial. The Italian IBD Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900085-8

Mesalamine capsules for the treatment of active Crohn's disease: results of a 16-week trial. Pentasa Crohn's Disease Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900085-8

Mesalamine in the treatment of mild to moderate active Crohn's ileitis: results of a randomized, multicenter trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900085-8

A controlled double blind multicenter study of the effectiveness of 5-aminosalicylic acid in patients with Crohn's disease in remission

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900085-8

Placebo-controlled trial of oral 5-ASA in relapse prevention of Crohn's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900085-8

Mesalamine in Crohn's disease with steroid-induced remission: effect on steroid withdrawal and remission maintenance, Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900085-8

A randomized, placebo-controlled, double-blind trial of mesalamine in the maintenance of remission of Crohn's disease. The Canadian Mesalamine for Remission of Crohn's Disease Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900085-8

Controlled trial of oral 5‐aminosalicylic acid for the prevention of early relapse in Crohn's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900085-8

Mesalazine (Mesasal/Claversal) 1.5 g b.d. vs. placebo in the maintenance of remission of patients with Crohn's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900085-8

Mesalamine in the maintenance treatment of Crohn's disease: a meta-analysis adjusted for confounding variables

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900085-8

Mesalamine in the prevention of endoscopic recurrence after intestinal resection for Crohn's disease. Italian Cooperative Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900085-8

Oral mesalazine (5-aminosalicylic acid; Asacol) for the prevention of post-operative recurrence of Crohn's disease. Gruppo Italiano per lo Studio del Colon e del Retto (GISC)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900085-8

Prophylactic mesalamine treatment decreases postoperative recurrence of Crohn's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900085-8

Prophylaxis of postoperative relapse in Crohn's disease with mesalamine: European Cooperative Crohn's Disease Study VI

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900085-8

Postoperative recurrence of Crohn's disease in relation to radicality of operation and sulfasalazine prophylaxis: a multicenter trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900085-8

Cortisone in ulcerative colitis; final report on a therapeutic trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900085-8

Clinical, biological, and endoscopic picture of attacks of Crohn's disease. Evolution on prednisolone. Groupe d'Etude Thérapeutique des Affections Inflammatoires Digestives.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900085-8

Treatment of ulcerative colitis with local hydrocortisone hemisuccinate sodium; a report on a controlled therapeutic trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900085-8

Treatment of ulcerative colitis with topical hydrocortisone hemisuccinate sodium; a controlled trial employing restricted sequential analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900085-8

Low dose steroids and clinical relapse in Crohn's disease: a controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900085-8

Frequency of glucocorticoid resistance and dependency in Crohn's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900085-8

Budesonide versus prednisone in the treatment of active Crohn's disease. The Israeli Budesonide Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900085-8

Oral budesonide is as effective as oral prednisolone in active Crohn's disease. The Global Budesonide Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900085-8

Oral budesonide for active Crohn's disease. Canadian Inflammatory Bowel Disease Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900085-8

A comparison of budesonide with prednisolone for active Crohn's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900085-8

A comparison of budesonide and mesalamine for active Crohn's disease. International Budesonide-Mesalamine Study Group.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900085-8

Low-dose budesonide treatment for prevention of postoperative recurrence of Crohn's disease: a multicentre randomized placebo-controlled trial. German Budesonide Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900085-8

Oral budesonide as maintenance therapy in Crohn's disease--results of a 12-month study. Global Budesonide Study Group.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900085-8

Oral budesonide as maintenance treatment for Crohn's disease: a placebo-controlled, dose-ranging study. Canadian Inflammatory Bowel Disease Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900085-8

Low dose oral pH modified release budesonide for maintenance of steroid induced remission in Crohn's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900085-8

Oral budesonide for prevention of postsurgical recurrence in Crohn's disease. The IOIBD Budesonide Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900085-8

Oral budesonide versus prednisolone in patients with active extensive and left-sided ulcerative colitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900085-8

Budesonide prolongs time to relapse in ileal and ileocaecal Crohn's disease. A placebo controlled one year study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900085-8

Comparative effects of quinolones on human mononuclear leucocyte functions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900085-8

Double blind, placebo controlled trial of metronidazole in Crohn's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900085-8

A controlled trial comparing ciprofloxacin with mesalazine for the treatment of active Crohn's disease. Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives (GETAID)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900085-8

Combination Ciprofloxacin and Metronidazole for Active Crohn’s Disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900085-8

Metronidazole plus ciprofloxacin in the treatment of active, refractory Crohn's disease: results of an open study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900085-8

Controlled trial of metronidazole treatment for prevention of Crohn's recurrence after ileal resection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900085-8

Controlled trial of intravenous metronidazole as an adjunct to corticosteroids in severe ulcerative colitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900085-8

A comparative study of metronidazole and sulfasalazine in active, not severe, ulcerative colitis. An Israeli multicenter trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900085-8

Long-term treatment of ulcerative colitis with ciprofloxacin: a prospective, double-blind, placebo-controlled study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900085-8

A controlled double blind study of azathioprine in the management of Crohn's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900085-8

Azathioprine combined with prednisolone or monotherapy with prednisolone in active Crohn's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900085-8

Double-blind withdrawal trial of azathioprine as maintenance treatment for Crohn's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900085-8

Azathioprine and 6-mercaptopurine in Crohn disease. A meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900085-8

Treatment of Crohn's disease with 6-mercaptopurine. A long-term, randomized, double-blind study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900085-8

A controlled trial of azathioprine in Crohn's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900085-8

Controlled trial of azathioprine in Crohn's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900085-8

Favorable effect of 6-mercaptopurine on fistulae of Crohn's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900085-8

Randomised controlled trial of azathioprine withdrawal in ulcerative colitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900085-8

Bone marrow toxicity caused by azathioprine in inflammatory bowel disease: 27 years of experience

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900085-8

6-Mercaptopurine in the management of inflammatory bowel disease: short- and long-term toxicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900085-8

Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900085-8

Olsalazine and 6-mercaptopurine-related bone marrow suppression: A possible drug-drug interaction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900085-8

Balsalazide and azathiprine or 6-mercaptopurine: evidence for a potentially serious drug interaction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900085-8

Sulphasalazine inhibition of thiopurine methyltransferase: possible mechanism for interaction with 6‐mercaptopurine and azathioprine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900085-8

Azathioprine or 6-mercaptopurine for inflammatory bowel disease: do risks outweigh benefits?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900085-8

Long-term neoplasia risk after azathioprine treatment in inflammatory bowel disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900085-8

Inflammatory bowel disease is not associated with an increased risk of lymphoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900085-8

Azathioprine for maintenance of remission in Crohn's disease: benefits outweigh the risk of lymphoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900085-8

Methotrexate for the Treatment of Crohn's Disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900085-8

A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group Investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900085-8

Methotrexate in chronic active ulcerative colitis: a double-blind, randomized, Israeli multicenter trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900085-8

Methotrexate induces clinical and histologic remission in patients with refractory inflammatory bowel disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900085-8

Preliminary report: cyclosporin in treatment of severe active ulcerative colitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900085-8

Cyclosporine in severe ulcerative colitis refractory to steroid therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900085-8

Intravenous cyclosporine versus intravenous corticosteroids as single therapy for severe attacks of ulcerative colitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900085-8

Low-Dose Cyclosporine for the Treatment of Crohn's Disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900085-8

European trial of cyclosporine in chronic active Crohn's disease: a 12-month study. The European Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900085-8

A placebo-controlled, double-blind, randomized trial of cyclosporine therapy in active chronic Crohn's disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900085-8

Clinical Outcome Following Treatment of Refractory Inflammatory and Fistulizing Crohn's Disease With Intravenous Cyclosporine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900085-8

Efficacy of cyclosporine in treatment of fistula of Crohn's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900085-8

Construction and initial characterization of a mouse-human chimeric anti-TNF antibody

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900085-8

The mouse/human chimeric monoclonal antibody cA2 neutralizes TNF in vitro and protects transgenic mice from cachexia and TNF lethality in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900085-8

Chimeric anti-TNF-α monoclonal antibody cA2 binds recombinant transmembrane TNF-α and activates immune effector functions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900085-8

Review article: targeting TNF alpha as a key cytokine in the inflammatory processes of Crohn's disease--the mechanisms of action of infliximab

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900085-8

A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900085-8

Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900085-8

Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: A European multicenter trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900085-8

Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900085-8

Infliximab for the treatment of fistulas in patients with Crohn's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900085-8

Infliximab for refractory ulcerative colitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900085-8

Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: a pilot study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900085-8

Review article: safety of infliximab in clinical trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900085-8

Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900085-8

The relationship between infliximab treatment and lymphoma in Crohn's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900085-8

An engineered human antibody to TNF (CDP571) for active Crohn's disease: a randomized double-blind placebo-controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900085-8

Treatment of ulcerative colitis with an engineered human anti‐TNFα antibody CDP571

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900085-8

Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900085-8

New life in a sleeper: thalidomide and Crohn's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900085-8

Thalidomide therapy for patients with refractory Crohn's disease: an open-label trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900085-8

An open-label pilot study of low-dose thalidomide in chronically active, steroid-dependent Crohn's disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900085-8

Efficacy of long-term treatment with thalidomide in children and young adults with Crohn disease: preliminary results.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900085-8

Tolerance towards resident intestinal flora in mice is abrogated in experimental colitis and restored by treatment with interleukin-10 or antibodies to interleukin-12

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900085-8

Interleukin-10-deficient mice develop chronic enterocolitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900085-8

Multiple doses of intravenous interleukin 10 in steroid-refractory Crohn's disease. Crohn's Disease Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900085-8

Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn's disease. The Interleukin 10 Inflammatory Bowel Disease Cooperative Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900085-8

Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn's disease. Crohn's Disease IL-10 Cooperative Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900085-8

Protection by recombinant human interleukin-11 against experimental TNB-induced colitis in rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900085-8

Preliminary evaluation of safety and activity of recombinant human interleukin 11 in patients with active Crohn's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900085-8

A placebo-controlled trial of ICAM-1 antisense oligonucleotide in the treatment of Crohn's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900085-8

Absence of efficacy of subcutaneous antisense ICAM-1 treatment of chronic active Crohn's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900085-8

Attenuation of colitis in the cotton-top tamarin by anti-alpha 4 integrin monoclonal antibody

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900085-8

Is Crohn's disease an immunodeficiency? A hypothesis suggesting possible early events in the pathogenesis of Crohn's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900085-8

A preliminary study of growth hormone therapy for Crohn's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900085-8

Utilisation of erythrocyte 6-thioguanine metabolite levels to optimise azathioprine therapy in patients with inflammatory bowel disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900085-8

Use of an intravenous steroid regimen in the treatment of acute Crohn's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900085-8

inferred from DOI database lookup

7 January 2021

based on heuristic

Controlled trial of azathioprine in chronic ulcerative colitis

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900085-8

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0025-7125(02)00085-8

1 reference

5 August 2017

1 reference